rdca presentation night 2023

Seniors - Documents

Registration - results, cv trans and gender diverse participation guidelines , child safe policies, forms / manuals, legend nomination, click here for rdca & yvca senior annual reports.

• Entertainment
• Competitions
• In Business
• Mail Community
• Mountain Views Star Mail
• Ranges Trader Star Mail
• Lilydale Star Mail
• Mount Evelyn Star Mail
• Ferntree Gully Belgrave Star Mail
• Upper Yarra Star Mail
• Digital Editions
• Classifieds
• Search Photos
• Our Community

Umpires needed for RDCA 2023-24 season

The Ringwood District Cricket Association (RDCA) is calling for new umpires to join their ranks ahead of the 2023/24 season.

Training and mentor programs for men, women, boys and girls to help get you up to speed, clued up on the laws of the game and confident ahead of the season’s start.

Umpiring is a paid position, with matches stretching from the Yarra Ranges to Ringwood, Warrandyte and Wantirna.

The RDCA has 183 Men’s and Women’s senior teams, 35 Veterans teams and 258 junior teams to cover playing in two-day, one-day and T20 matches.

Anyone interested can contact Adam Kuklych at [email protected] or on 0475 451 101 or Jordan Russell at [email protected] or on 0413 357 444.

Healesville 2nd XI fall short in season decider

Ex-afl player signs in local football club, victorian government plan to protect green wedge zones announced, little athletics season ends with presentation day, man injured after crash.

Rare Disease Innovation and Data Sharing Accelerated by New RDCA-DAP Program

C-Path, NORD and FDA host annual meeting, demonstration and launch of new rare disease data and analytics platform.

TUCSON , Ariz. and WASHINGTON , September 15, 2021 — The Rare Disease Cures Accelerator-Data and Analytics Platform initiative ( RDCA-DAP ® ) officially launched its next phase on Tuesday establishing itself as the leading platform to accelerate rare disease treatment innovation. The launch was part of an all-day virtual workshop and annual meeting of rare disease stakeholders, featuring a platform demonstration, industry expert presentations and attendance by over 400 patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists.

RDCA-DAP is an FDA-funded initiative that will serve as a centralized and standardized base to host and share de-identified rare diseases data and to support treatment innovation. It was created through a partnership between Critical Path Institute (C-Path), the National Organization for Rare Disorders (NORD ® ) and the U.S. Food and Drug Administration (FDA) and has grown to include many others throughout the rare disease community.

“There is a lot of enthusiasm for seeing this platform become all it can be for patients and drug developers. It is not just about the data. This is a place to generate solutions in a highly collaborative way,” said Jeff Barrett, Ph.D., F.C.P., C-Path Senior Vice President and RDCA-DAP Lead. “We expect RDCA-DAP to be a place to promote candid dialogue, optimize patient selection and trial design, and co-develop the tools to further de-risk decision making for rare disease drug development.”

After a public premiere showcasing the functionality of the platform, presentations throughout the day emphasized how RDCA-DAP will curate data to break down silos, provided insight into the platform’s development and testing and showcased the importance of RDCA-DAP from the perspective of critical stakeholders, including academic, clinical, regulatory and patient communities.

On the importance of incorporating patients’ perspectives through RDCA-DAP, Theresa Mullin, Ph.D., Associate Director for Strategic Initiatives, Center for Drug Evaluation and Research (CDER), FDA, said, “Identifying the burdens of disease and current therapies that matter most, what can be measured, and what would constitute a meaningful change, can provide insight on the clinical context for regulatory review and potentially more direct evidence of drug benefits and risks when collected using valid and reliable measures and tools.”

A total of 31 speakers and panelists from patient organizations and regulatory, industry and academic fields participated in the workshop. Five patient profiles underscoring the importance of data sharing were also highlighted. Those interested in viewing the workshop and accessing supplemental information can do so here .

“Patient owned data collected by patient groups are less likely to get stuck in a silo,” said Ed Neilan, M.D., Ph.D., Chief Medical and Scientific Officer, NORD. “Of the over 7,000 estimated rare diseases, more 90% have no FDA approved treatment. And currently the attention of the pharmaceutical industry is on 100 or 200 of these rare diseases. RDCA-DAP may bring attention to rare diseases that might otherwise remain relatively neglected.”

To learn more and request access to RDCA-DAP, apply directly on the platform at https://portal.rdca.c-path.org . To submit critical rare disease data, contact the project team at [email protected] or visit c-path.org/programs/rdca-dap and rarediseases.org/rdca-dap .

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 56.5% funded by FDA/HHS, totaling $16,749,891, and 43.5% funded by non-government source(s), totaling $12,895,366. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government. For more information, please visit FDA.gov .

About Critical Path Institute Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org  and  c-path.eu .

About the National Organization for Rare Disorders (NORD) ® The National Organization for Rare Disorders (NORD) is the leading independent advocacy organization representing all patients and families affected by rare diseases in the United States. NORD began as a small group of patient advocates that formed a coalition to unify and mobilize support to pass the Orphan Drug Act of 1983. Since then, the organization has led the way in voicing the needs of the rare disease community, driving supportive policies, furthering education, advancing medical research, and providing patient and family services for those who need them most. Together with over 330 disease-specific member organizations, more than 15,000 Rare Action Network advocates across all 50 states, and national and global partners, NORD delivers on its mission to improve the lives of those impacted by rare diseases. Visit rarediseases.org .

Media Contacts:

Kissy Black C-Path 615.310.1894 [email protected]

Rohan Narayanan NORD 571-255-0042 [email protected]

2023-24 Presentation night

Fri Apr 12 2024 at 07:30 pm

Weston Creek Labor Club | Canberra, CT

Where is it happening?

Event Location & Nearby Stays:

Host or Publisher Weston Creek Molonglo Cricket Club

It's more fun with friends. share with friends, discover more events in canberra.

Canberra Southern Cross Club - Woden

NFSA Canberra

Ronin Games Woden

Y Suites on Moore

The Baso Canberra

Blackbird.Canberra

10 Watson st Turner ACT 2601

Hellenic Club of Canberra

Canberra - TBA

Virtual Workshop

Canberra Training Center

What's Happening Next in Canberra?

RDCA Special Interest Group

9th Reisman Diagnostic Creativity Assessment (RDCA) Special Interest Group

Date: 26 july 2023, topic: “how do creativity and motivation relate as assessed by the rdca and rdma*”, special event: 2nd frc lecture & ‘freddie reisman award for contributions to transactional research in creativity and motivation’, guest speaker: jeff westphal (tbc).

The Reisman Diagnostic Creativity Assessment Special Interest Group (RDCA SIG) was inaugurated on August 11, 2015 at the 2015 edition of the KIE Conference. The RDCA SIG was constituted to honour an aspect of the work of Dr Fredricka K. Reisman, immediate-past president of the American Creativity Association and Co-Director of the Drexel-Torrance Centre for Creativity and Innovation, Philadelphia, USA. The RDCA SIG Presentations is moderated by Dr Larry Keiser, Clinical Assistant Professor and Director of Special Projects & Certification Officer at Drexel University, USA, and a co-developer of the RDCA tool. The RDCA SIG has done a number of presentations in the past seven years – including The Power of Becoming Aware of Our Creative Strengths and Weaknesses—and How this Helped Us Cope with Life Changing Happenings! (2018) and A creative exploration of autism, dyslexia and dyscalculia (2017).

*RDMA stands for the Reisman Diagnostic Motivation Assessment. Recently, three forms of the RDMA were created for corporate employees, school teachers and students – grade 8 (school children aged 13 -14) through (post) graduation students.

For more details, please visit RDCA SIG here

Username or Email Address

Remember Me

Cart has 0 tickets.

Fhcc presentation night - season 2023/24.

Mulgrave Country Club - Panorama Room Corner of Wellington and Jells Roads, Wheelers Hill VIC 3150

Contact Details

Contact event organiser, join wait list, sorry, there are no available tickets for this event. please sign up to the wait list (optional)., your name has been added to the wait list for this event. the event organiser will contact you through your email address once there are available seats / slots..

Sorry, there appears to have been an error. Please try again later.

Contact Form

Ask the event organiser a question, get your tickets resent to you or book to this event.

Use this form to message the event organiser if you have a question about the event.

Contact name:

Contact phone:

You can review the event organiser's terms and conditions here .

Your email has been sent.

The organiser will be sent the details of this message.

Resend recently purchased tickets to our events to your email.

Enter email to start search